Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death
about
Tuberculosis and HIV co-infectionImmunologic changes in frail older adultsWhen to start antiretroviral therapy: as soon as possibleImpact of antiretroviral therapy (ART) timing on chronic immune activation/inflammation and end-organ damageHIV and aging: emerging research issuesPersistent high mortality in advanced HIV/TB despite appropriate antiretroviral and antitubercular therapy: an emerging challengeImpact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infectionThe Effect of a Community-Based Exercise Program on Inflammation, Metabolic Risk, and Fitness Levels Among Persons Living with HIV/AIDS.Enhanced effector function of CD8(+) T cells from healthy controls and HIV-infected patients occurs through thrombin activation of protease-activated receptor 1.Correlates of elevated interleukin-6 and C-reactive protein in persons with or at high risk for HCV and HIV infections.X4 viruses are frequently archived in patients with long-term HIV infection but do not seem to influence the "inflamm-aging" process.Systemic effects of inflammation on health during chronic HIV infectionHIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality.Immune activation and HIV persistence: considerations for novel therapeutic interventions.Inflammatory cytokines and mortality in a cohort of HIV-infected adults with alcohol problems.Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial.Empiric deworming and CD4 count recovery in HIV-infected Ugandans initiating antiretroviral therapy.Residual immune dysregulation syndrome in treated HIV infection.Can early therapy reduce inflammation?Clinical and immunologic predictors of death after an acute opportunistic infection: results from ACTG A5164.Dynamics of adrenal steroids are related to variations in Th1 and Treg populations during Mycobacterium tuberculosis infection in HIV positive personsInflammatory cytokines drive CD4+ T-cell cycling and impaired responsiveness to interleukin 7: implications for immune failure in HIV disease.Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection.Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment.Association of markers of hemostasis with death in HIV-infected women.Immune activation and HIV persistence: implications for curative approaches to HIV infection.Association of soluble CD14 and inflammatory biomarkers with HIV-2 disease progression.Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individualsPredictive value of liver enzymes and inflammatory biomarkers for the severity of liver fibrosis stage in HIV/HCV co-infected patientsInitiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activationParadoxical tuberculosis immune reconstitution inflammatory syndrome (TB-IRIS) in HIV patients with culture confirmed pulmonary tuberculosis in India and the potential role of IL-6 in prediction.Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfected patients.HIV-1 infection induces strong production of IP-10 through TLR7/9-dependent pathwaysHIV-1 infected lymphoid organs upregulate expression and release of the cleaved form of uPAR that modulates chemotaxis and virus expression.IL-1Β enriched monocytes mount massive IL-6 responses to common inflammatory triggers among chronically HIV-1 infected adults on stable anti-retroviral therapy at risk for cardiovascular diseaseProspective antiretroviral treatment of asymptomatic, HIV-1 infected controllers.Immune reconstitution inflammatory syndrome in HIV-infected patientsAntifibrotic therapy in simian immunodeficiency virus infection preserves CD4+ T-cell populations and improves immune reconstitution with antiretroviral therapy.Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study.Community perspective on the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
P2860
Q21131403-2EBC2219-0725-492B-BC60-9C7AEB39D22DQ26866941-7538A3F0-EADF-49A0-8269-B7D4203AECB9Q27006767-8046E1DA-F32F-48CE-A5D9-AFCF9298F16EQ27014077-1A64130A-6443-4A4B-B857-EB606469043CQ27016011-AD6652C2-E9C2-45DB-8B9F-89FE4EC0E597Q28088557-665299E7-D220-4521-9929-1D7057FA9D84Q28481938-8438DE55-3A6F-411B-9822-018FF52F5797Q30381883-73D909FB-F50A-43E2-B810-F94DECA2C4EDQ30532710-3FDF51E3-D437-4991-B3F3-39C076351695Q30558355-0FA9A079-A083-403E-BFFC-7F42A276C862Q31117473-B348DAE7-BB26-4FC7-92F9-29EC8569DC7EQ33577551-C24698D9-9BAD-4E93-8B9B-B9049BA93C20Q33618542-198B4BC9-00AB-4FF5-834D-1DF3946D5D9AQ33698781-43371BD5-9006-487D-ABDF-4CE5B1B52921Q33926735-31509977-FA6E-44A2-8AC6-4669F814488BQ33934080-02387D8F-0971-4E59-BA19-2283D828CBE9Q34016057-06A4C61C-038A-4F76-BFC2-1F948C229398Q34020121-1047FCFC-1B9C-4AAF-8EA4-9F374DD2968BQ34159822-8C7BE181-3048-4CAA-AE44-39308E4531CFQ34202331-6CD520A0-290A-447D-A3A9-1241C350E1E3Q34202804-F49484F0-7613-4CAF-9F32-152D49C941FDQ34229695-7016C511-647E-4C6E-87B8-DF30547DC19EQ34315572-7691F727-D8D3-4CC2-BDE9-6A3BC6BA65E8Q34315579-1630DA7A-BD7B-4FC9-801C-D87D7D347039Q34342193-45856278-DDF2-47F5-AD6A-84E36387088CQ34351320-DF3917C1-B503-47D4-AFC5-14FB244A4C6AQ34387349-D0633AA2-8F69-4CE3-A4EE-15DD46EB4A4CQ34612385-AB0588B3-776E-466E-9065-3EF14D3031DEQ34634839-48193108-3C66-4BDA-B5A1-1B4472CF1E85Q34682171-E13A03A1-37EF-41DC-8E83-B11A7A0BFFD3Q34730629-AA7A0B05-7A43-43FB-9AE0-7B7CBD1D808EQ34749550-E6090FB6-96A3-4B6C-BAE9-39A7075B25CAQ34889163-DF15DAC3-74ED-427E-A008-AF0258053D6CQ34907139-9454D482-725C-4744-8B2B-30EAED4353C0Q35005668-2573DE58-5F00-40FD-A373-D3E8F09B1241Q35018065-ABB734D0-AAC1-4E3E-B717-5494100DFC70Q35100818-B18D3A09-B3C7-4357-9581-EA42CCE58327Q35102598-6AE3B009-A707-4A33-BD55-DE085629550FQ35109483-653328EC-54F5-4AAB-9DA4-82B5F025C84FQ35124919-44930A20-BE03-451D-9D4A-9CB323548DFA
P2860
Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Higher levels of CRP, D-dimer, ...... ncreased risk of AIDS or death
@ast
Higher levels of CRP, D-dimer, ...... ncreased risk of AIDS or death
@en
Higher levels of CRP, D-dimer, ...... ncreased risk of AIDS or death
@nl
type
label
Higher levels of CRP, D-dimer, ...... ncreased risk of AIDS or death
@ast
Higher levels of CRP, D-dimer, ...... ncreased risk of AIDS or death
@en
Higher levels of CRP, D-dimer, ...... ncreased risk of AIDS or death
@nl
prefLabel
Higher levels of CRP, D-dimer, ...... ncreased risk of AIDS or death
@ast
Higher levels of CRP, D-dimer, ...... ncreased risk of AIDS or death
@en
Higher levels of CRP, D-dimer, ...... ncreased risk of AIDS or death
@nl
P2093
P2860
P50
P356
P1476
Higher levels of CRP, D-dimer, ...... ncreased risk of AIDS or death
@en
P2093
Adam Rupert
Camille E Puronen
INSIGHT Study Group
James D Neaton
Jason V Baker
Katherine Huppler Hullsiek
Richard M Novak
P2860
P304
P356
10.1093/INFDIS/JIR134
P407
P577
2011-06-01T00:00:00Z